ArticleFrontiers in oncology2026
TACE combined with DynaCT-guided MWA in the treatment of high-risk location liver cancers with ≤5 cm tumor size.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We aimed to investigate the safety and therapeutic effectiveness of the combination of transcatheter arterial chemoembolization (TACE) with DynaCT-guided microwave ablation (MWA) for the treatment of liver tumors ≤5 cm located in high-risk areas. Methods: The clinical materials of 55 newly diagnosed liver cancer patients with ≤5 cm unifocal lesion admitted to our department from September 2019 to January 2021 were collected. The liver function change, adverse reactions, tumor control rates, cumulative survival rates, overall survival (OS), and progression-free survival (PFS) of the group were compared. Results: All participants successfully underwent combination treatment with TACE and MWA. According to the Common Terminology Criteria for Adverse Events (CTCAE5.0), adverse events (AEs) and the majority of the complications were classified as grade 1 or 2, involving mild symptoms that required either no intervention or only local, noninvasive management. The mean OS in the high-risk location group was 41.0 months (95%CI = 39.6-42.5), and the mean PFS was 31.2 months (95%CI = 30.7-31.7). The Kaplan-Meier survival curves for OS and PFS are shown in Conclusions: TACE combined with sequential DynaCT-guided MWA may be a safe and promising treatment option for liver cancers ≤5 cm in high-risk locations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.